Keros Therapeutics, Inc. (KROS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Keros Therapeutics, Inc. (KROS) Healthcare & Pipeline Overview

Keros Therapeutics, Inc. specializes in developing novel therapies for hematological and musculoskeletal disorders, with a focus on high unmet medical needs, leveraging advanced protein and small molecule therapeutics to address conditions such as anemia and bone loss.

What Is the Investment Thesis for KROS?

Keros Therapeutics, Inc. presents a compelling case for growth, driven by its innovative product pipeline targeting significant unmet medical needs in hematological and musculoskeletal disorders. The lead candidate, KER-050, is currently in clinical trials, with potential market entry expected in the next few years, addressing a market valued at over $10 billion for anemia treatments alone. Additionally, KER-047 and KER-012 offer further avenues for growth, with the global osteoporosis treatment market projected to exceed $30 billion by 2027. The company’s strong gross margin of 96.5% indicates efficient cost management, although it currently operates at a negative profit margin of -256.6%. As Keros progresses through clinical trials, successful outcomes could enhance its market position and attract partnerships for commercialization, bolstering its financial metrics significantly.

Based on FMP financials and quantitative analysis

KROS Key Highlights

Market Cap of $357M reflects investor interest in innovative biopharmaceuticals.

• P/E ratio of -1.78 indicates current losses as the company invests heavily in R&D.
• Gross margin of 96.5% highlights operational efficiency in product development.
• Negative free cash flow of $-0.06 billion suggests ongoing investment in clinical trials and product development.
• Beta of 0.95 indicates stock price stability relative to market fluctuations.

Who Are KROS's Competitors?

KROS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are KROS's Key Strengths?

Innovative product candidates targeting significant unmet medical needs.

• Strong gross margin indicating operational efficiency.
• Experienced leadership with a focus on R&D.

What Are KROS's Weaknesses?

Current negative profit margin due to high R&D expenses.

• Limited product portfolio as a clinical-stage company.
• Dependence on successful clinical trial outcomes.

What Could Drive KROS Stock Higher?

Results from Phase 1 clinical trials for KER-047 expected in late 2026.

• Anticipated data release for KER-012 clinical trials in early 2027.
• Development of KER-050 with potential market entry projected within the next 2-3 years.

What Are the Key Risks for KROS?

Negative return on equity (-17.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles could delay product approvals.
• High R&D costs may impact financial stability.
• Competition from established biopharmaceutical companies could affect market share.

What Are the Growth Opportunities for KROS?

• Expansion into Anemia Treatment: KER-050 targets low blood cell counts, addressing a market valued at over $10 billion. With clinical trials progressing, Keros could capture significant market share upon successful product launch, projected within the next 2-3 years.
• Development of KER-047: This small molecule candidate focuses on anemia treatment and is currently in Phase 1 trials. With the global anemia treatment market anticipated to grow significantly, KER-047 could provide a substantial revenue stream, especially if it demonstrates efficacy and safety in trials.
• Potential of KER-012 in Osteoporosis: KER-012 aims to treat osteoporosis and related bone loss disorders, a market projected to exceed $30 billion by 2027. Successful clinical outcomes could position Keros as a key player in this lucrative segment.
• Strategic Partnerships: Collaborations with larger pharmaceutical companies for co-development or commercialization could enhance Keros's market reach and financial stability, particularly as it advances its product candidates through clinical trials.
• Geographic Expansion: As Keros Therapeutics develops its products, expanding into international markets could significantly increase its customer base and revenue potential, especially in regions with high prevalence of hematological and musculoskeletal disorders.

What Threats Does KROS Face?

• Intense competition from established biopharmaceutical companies.
• Regulatory challenges in drug approval processes.
• Market volatility impacting investor sentiment.

What Are KROS's Competitive Advantages?

• Strong focus on high unmet medical needs differentiates Keros from competitors.
• Innovative product pipeline with multiple candidates in clinical trials.
• High gross margin reflects operational efficiency and potential profitability.
• Expertise in protein therapeutics and small molecule development.

What Does KROS Do?

Founded in 2015 and headquartered in Lexington, Massachusetts, Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients suffering from hematological and musculoskeletal disorders. The company was established to address the significant unmet medical needs in these areas, particularly focusing on conditions like anemia and thrombocytopenia associated with myelodysplastic syndromes and myelofibrosis. Keros Therapeutics is advancing its lead product candidate, KER-050, which is designed to treat low blood cell counts, and is currently in clinical trials. Additionally, the company is developing KER-047, a small molecule candidate aimed at treating anemia, which is also in Phase 1 clinical trials. Another promising candidate, KER-012, is being investigated for its potential to treat disorders linked to bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. With a dedicated team of 163 employees, Keros Therapeutics is positioned to make significant contributions to the biopharmaceutical landscape, focusing on innovative therapies that can improve patient outcomes in areas with high medical need.

What Products and Services Does KROS Offer?

• Develop innovative treatments for hematological disorders.
• Focus on musculoskeletal disorder therapies.
• Advance clinical-stage biopharmaceutical products.
• Conduct clinical trials to evaluate product efficacy and safety.
• Target high unmet medical needs in specific patient populations.
• Utilize both protein therapeutics and small molecules in product development.

How Does KROS Make Money?

• Revenue generation through the commercialization of successful drug candidates.
• Funding through strategic partnerships and collaborations.
• Investment in R&D to develop innovative therapies.
• Potential licensing agreements for product distribution.

What Industry Does KROS Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in areas addressing unmet medical needs. The global biotechnology market is projected to grow at a CAGR of approximately 7.4%, driven by advancements in genetic research, personalized medicine, and novel therapeutic solutions. Keros Therapeutics operates in a competitive landscape with several established players, but its focused approach on hematological and musculoskeletal disorders positions it uniquely to capture market share in these high-demand areas.

Who Are KROS's Key Customers?

• Patients suffering from hematological disorders.
• Individuals with musculoskeletal conditions.
• Healthcare providers and hospitals.
• Pharmaceutical partners for drug development and distribution.

Keros Therapeutics, Inc. (KROS) Valuation Context

Valued at $357M, KROS is classified as a small-cap stock. Analyst price targets span from $18.00 to $23.00, with a consensus of $20.33. At the current price of $11.17, that implies approximately 82% upside potential. Relative to its peer group, KROS's quantitative score of 29/100 is below the peer average of 75/100.

KROS Revenue & Earnings Trend

In Q2 FY2026, KROS generated $0 in top-line revenue, marking a sequential decrease of 100.0%. The company recorded a net loss of $28.7M, with diluted EPS of $-1.45. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, KROS averaged $-0.92 in diluted EPS.

Company Profile

Keros Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO Jasbir S. Seehra. KROS has traded publicly since 2020.

Return on equity for Keros Therapeutics, Inc. stands at -17.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 22.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.1%, the inverse of the P/E and a quick read on earnings relative to price.

Keros Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.12 places it in the safe zone, indicating low near-term bankruptcy risk.

Keros Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4538.3% above estimates on average.

Over the past six months, Keros Therapeutics, Inc. insiders filed 27 SEC Form 4 transactions — 9 sales and 18 purchases. On net that is roughly 88K shares acquired (about $414K) — insiders putting money in tends to read as conviction.

KROS Financials

KROS Latest News

KROS Analyst Consensus

KROS MoonshotScore

What Investors Ask About Keros Therapeutics, Inc. (KROS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources